INTRODUCTION: Neuroblastoma (NB) is the most frequent indication for extracranial pediatric radiotherapy. As long-term survival of high-risk localized NB has greatly improved, we reviewed treatment-related late toxicities in pediatric patients who received postoperative radiotherapy (RT) for localized NB within two French prospective clinical trials: NB90 and NB94. PATIENTS AND METHODS: From 1990-2000, 610 children were enrolled. Among these, 35 were treated with induction chemotherapy, surgery, and RT. The recommended RT dose was 24 Gy at ≤ 2 years, 34 Gy at > 2 years, ± a 5 Gy boost in both age groups. RESULTS: The 22 patients still alive after 5 years were analyzed. The median follow-up time was 14 years (range 5-21 years). Late effects after therapy occurred in 73 % of patients (16/22), within the RT field for 50 % (11/22). The most frequent in-field effects were musculoskeletal abnormalities (n = 7) that occurred only with doses > 31 Gy/1.5 Gy fraction (p = 0.037). Other effects were endocrine in 3 patients and second malignancies in 2 patients. Four patients presented with multiple in-field late effects only with doses > 31 Gy. CONCLUSION: After a median follow-up of 14 years, late effects with multimodality treatment were frequent. The most frequent effects were musculoskeletal abnormalities and the threshold for their occurrence was 31 Gy.
INTRODUCTION:Neuroblastoma (NB) is the most frequent indication for extracranial pediatric radiotherapy. As long-term survival of high-risk localized NB has greatly improved, we reviewed treatment-related late toxicities in pediatric patients who received postoperative radiotherapy (RT) for localized NB within two French prospective clinical trials: NB90 and NB94. PATIENTS AND METHODS: From 1990-2000, 610 children were enrolled. Among these, 35 were treated with induction chemotherapy, surgery, and RT. The recommended RT dose was 24 Gy at ≤ 2 years, 34 Gy at > 2 years, ± a 5 Gy boost in both age groups. RESULTS: The 22 patients still alive after 5 years were analyzed. The median follow-up time was 14 years (range 5-21 years). Late effects after therapy occurred in 73 % of patients (16/22), within the RT field for 50 % (11/22). The most frequent in-field effects were musculoskeletal abnormalities (n = 7) that occurred only with doses > 31 Gy/1.5 Gy fraction (p = 0.037). Other effects were endocrine in 3 patients and second malignancies in 2 patients. Four patients presented with multiple in-field late effects only with doses > 31 Gy. CONCLUSION: After a median follow-up of 14 years, late effects with multimodality treatment were frequent. The most frequent effects were musculoskeletal abnormalities and the threshold for their occurrence was 31 Gy.
Authors: L E Cohen; J H Gordon; E Y Popovsky; S Gunawardene; E Duffey-Lind; L E Lehmann; L R Diller Journal: Bone Marrow Transplant Date: 2014-01-20 Impact factor: 5.483
Authors: Rochelle Bagatell; Maja Beck-Popovic; Wendy B London; Yang Zhang; Andrew D J Pearson; Katherine K Matthay; Tom Monclair; Peter F Ambros; Susan L Cohn Journal: J Clin Oncol Date: 2008-12-01 Impact factor: 44.544
Authors: Caroline Laverdière; Qi Liu; Yutaka Yasui; Paul C Nathan; James G Gurney; Marilyn Stovall; Lisa R Diller; Nai-Kong Cheung; Suzanne Wolden; Leslie L Robison; Charles A Sklar Journal: J Natl Cancer Inst Date: 2009-07-31 Impact factor: 11.816
Authors: H Rubie; C Coze; D Plantaz; C Munzer; A S Defachelles; C Bergeron; C Thomas; P Chastagner; D Valteau-Couanet; J Michon; V Mosseri; O Hartmann Journal: Br J Cancer Date: 2003-11-03 Impact factor: 7.640
Authors: B De Bernardi; V Mosseri; H Rubie; V Castel; A Foot; R Ladenstein; G Laureys; M Beck-Popovic; A F de Lacerda; A D J Pearson; J De Kraker; P F Ambros; Y de Rycke; M Conte; P Bruzzi; J Michon Journal: Br J Cancer Date: 2008-09-02 Impact factor: 7.640
Authors: Steve E Braunstein; Wendy B London; Susan G Kreissman; Judith G Villablanca; Andrew M Davidoff; Kenneth DeSantes; Robert P Castleberry; Kevin Murray; Lisa Diller; Katherine Matthay; Susan L Cohn; Barry Shulkin; Daniel von Allmen; Marguerite T Parisi; Collin Van Ryn; Julie R Park; Michael P La Quaglia; Daphne A Haas-Kogan Journal: Pediatr Blood Cancer Date: 2019-04-09 Impact factor: 3.167
Authors: Dana L Casey; Brian H Kushner; Nai-Kong V Cheung; Shakeel Modak; Ellen M Basu; Stephen S Roberts; Michael P LaQuaglia; Suzanne L Wolden Journal: Int J Radiat Oncol Biol Phys Date: 2019-02-11 Impact factor: 7.038
Authors: Dana L Casey; Brian H Kushner; Nai-Kong V Cheung; Shakeel Modak; Michael P LaQuaglia; Suzanne L Wolden Journal: Int J Radiat Oncol Biol Phys Date: 2016-05-27 Impact factor: 7.038
Authors: Daniel von Allmen; Andrew M Davidoff; Wendy B London; Collin Van Ryn; Daphne A Haas-Kogan; Susan G Kreissman; Geetika Khanna; Nancy Rosen; Julie R Park; Michael P La Quaglia Journal: J Clin Oncol Date: 2016-11-21 Impact factor: 44.544
Authors: Matthew J Ferris; Hasan Danish; Jeffrey M Switchenko; Claudia Deng; Bradley A George; Kelly C Goldsmith; Karen J Wasilewski; W Thomas Cash; Mohammad K Khan; Bree R Eaton; Natia Esiashvili Journal: Int J Radiat Oncol Biol Phys Date: 2016-11-27 Impact factor: 7.038